LLY.F - Eli Lilly and Company

Frankfurt - Frankfurt Delayed Price. Currency in EUR
99.73
-1.51 (-1.49%)
At close: 8:00AM CEST
Stock chart is not supported by your current browser
Previous Close101.24
Open99.73
Bid100.88 x 30000
Ask100.98 x 30000
Day's Range99.73 - 99.73
52 Week Range89.48 - 116.87
Volume80
Avg. Volume162
Market Cap95.263B
Beta (3Y Monthly)0.17
PE Ratio (TTM)12.58
EPS (TTM)7.93
Earnings DateN/A
Forward Dividend & Yield2.32 (2.29%)
Ex-Dividend Date2019-08-14
1y Target EstN/A
  • 3 Top Diabetes Stocks to Watch in August
    Motley Fool9 hours ago

    3 Top Diabetes Stocks to Watch in August

    These three diabetes-oriented companies should be on your radar right now.

  • Longtime Genentech exec retiring as new CEO settles in
    American City Business Journals2 days ago

    Longtime Genentech exec retiring as new CEO settles in

    In her decade with Genentech, Sandra Horning has served under four CEOs, the most recent one joining March 1.

  • Better Buy: Eli Lilly vs. GlaxoSmithKline
    Motley Fool3 days ago

    Better Buy: Eli Lilly vs. GlaxoSmithKline

    Which stock wins in this big-pharma matchup?

  • How AbbVie Plans To Take On Pfizer, Lilly — And Kick Its Humira Habit
    Investor's Business Daily5 days ago

    How AbbVie Plans To Take On Pfizer, Lilly — And Kick Its Humira Habit

    Shares of AbbVie leapt higher Friday after the Food and Drug Administration approved its new rheumatoid arthritis treatment — a potential rival to drugs from Eli Lilly and Pfizer.

  • The Top Pharma Stocks for 2019
    Investopedia6 days ago

    The Top Pharma Stocks for 2019

    Find out how the pharmaceutical industry is thriving, the new drugs that are coming to market, and the top pharmaceutical stocks for 2019.

  • Benzinga8 days ago

    Lilly's Psoriasis Drug Found Superior To J&J's Tremfya In Phase 4 Study

    Lilly said Tuesday ahead of the market open that Talz, a monoclonal antibody that selectively binds with interleukin 17A (IL-17A) cytokine, met the primary and all major secondary endpoints up to 12 weeks in the Phase 4 IXORA-R study. Taltz has been approved for treating adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy, and also for adults with psoriatic arthritis.

  • 8 Stocks That Have Paid a Dividend for 125 (or More) Consecutive Years
    Motley Fool8 days ago

    8 Stocks That Have Paid a Dividend for 125 (or More) Consecutive Years

    Income stocks don't get more consistent than this.

  • How one Boston startup rode the diabetes investment wave to raise $126M
    American City Business Journals8 days ago

    How one Boston startup rode the diabetes investment wave to raise $126M

    When Boston University professor Ed Damiano set out to raise a new tranche of funding for a startup last year, his hopes were low: Diabetes device makers were struggling to raise money in a field that was being increasingly dominated by two players.

  • Financial Times10 days ago

    US patients struggle to obtain Eli Lilly’s half-price insulin

    US diabetes patients are struggling to obtain Eli Lilly’s half-price insulin, which it unveiled shortly before being grilled by Congress about the soaring price of the essential medicine. Only about 3 per cent of insurance claims for Eli Lilly’s insulin were for the cheaper, generic version Insulin Lispro, compared with 97 per cent for its brand name Humalog, according to recent data from GoodRx, an app that tracks drug prices. Many pharmacists do not know that the cheaper version is available — and other patients cannot access it because their insurance or pharmacy benefit manager has not put it on formulary, the list of drugs that are covered.

  • Dicerna Pharmaceuticals Inc (DRNA) Q2 2019 Earnings Call Transcript
    Motley Fool11 days ago

    Dicerna Pharmaceuticals Inc (DRNA) Q2 2019 Earnings Call Transcript

    DRNA earnings call for the period ending June 30, 2019.

  • Reuters13 days ago

    UPDATE 1-Study shows Apple devices in combo with apps could identify dementia

    Drugmaker Eli Lilly said on Thursday early results from a study suggest that Apple Inc devices, including the iPhone, in combination with digital apps could differentiate people with mild Alzheimer's disease dementia and those without symptoms. The study, tested in 113 participants over the age of 60, was conducted by Apple along with Eli Lilly and Evidation Health. The Apple devices were used along with the Beddit sleep monitoring device and digital apps in the study.

  • Horizon Stock Pops On Beat And Raise As Another Drugmaker Reverses
    Investor's Business Daily14 days ago

    Horizon Stock Pops On Beat And Raise As Another Drugmaker Reverses

    Horizon Therapeutics stock popped Wednesday after its gout treatment, Krystexxa, drove a beat and raise in the second quarter. Adjusted Horizon earnings also came in better than expected.

  • Which Pharmaceutical Stocks Are Outperforming All Other Stocks?
    Investor's Business Daily15 days ago

    Which Pharmaceutical Stocks Are Outperforming All Other Stocks?

    The best pharmaceutical stocks to buy have commonalities: strong Composite Ratings and Relative Strength Ratings.

  • Benzinga16 days ago

    Eli Lilly Announces Positive Results For Emgality

    Eli Lilly (NYSE: LLY ) has announced positive results for Emgality , which is the preventive treatment of chronic and episodic migraine in patients. The drug has met the primary and all key secondary outcomes ...

  • 3 Lung Cancer Stocks That Could Soar in September
    Motley Fool17 days ago

    3 Lung Cancer Stocks That Could Soar in September

    These industry giants could make big moves after this year's World Conference on Lung Cancer.

  • Eli Lilly and Company (LLY) Q2 2019 Earnings Call Transcript
    Motley Fool21 days ago

    Eli Lilly and Company (LLY) Q2 2019 Earnings Call Transcript

    LLY earnings call for the period ending June 30, 2019.

  • Eli Lilly's Solid Q2 Results: What You'll Want to Know
    Motley Fool22 days ago

    Eli Lilly's Solid Q2 Results: What You'll Want to Know

    The big drugmaker topped Wall Street estimates and upped its full-year guidance.

  • Eli Lilly tops profit estimates on boost from diabetes drugs
    Reuters22 days ago

    Eli Lilly tops profit estimates on boost from diabetes drugs

    The drugmaker has been working to retain its dominant position in the diabetes market, as its top-sellers, including insulin injection Humalog, lose market share to rivals, amid political scrutiny over soaring healthcare costs. Lilly is also banking on its newer treatments such as Emgality, which won U.S. approval to treat migraine last year and has been touted as a growth driver for Lilly. Lilly in March agreed to offer a half-priced version of Humalog after coming under intense pressure from U.S. politicians to lower drug costs.

  • Benzinga22 days ago

    Eli Lilly Reports Q2 Earnings Beat

    Eli Lilly (NYSE: LLY ) reported quarterly earnings of $1.50 per share, which beat the analyst consensus estimate of $1.45 by 3.45%. This is unchanged from the same period last year. The company reported ...

  • Benzinga22 days ago

    The Daily Biotech Pulse: European Cheer For Merck, Legal Victory For Coherus, Medpace Picks Up On Earnings

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 29) Acasti Pharma Inc (NASDAQ: ACST ) Array Biopharma Inc ...

  • Reuters22 days ago

    UPDATE 3-Newer drugs help Eli Lilly top Wall Street quarterly profit estimate

    Eli Lilly and Co reported a second-quarter profit that topped Wall Street estimates and raised its 2019 earnings forecast on Tuesday, as higher demand for newer drugs offset increased discounts for the U.S. Medicare program and sales declines of medicines that lost patent protection. The drugmaker has been working to retain its position as a leader in diabetes care with newer drugs like Trulicity, Jardiance and Basaglar, as its top-selling insulin product Humalog faces increased competition and political pressure over the soaring cost of life-sustaining insulin. Lilly is counting on new drugs in other therapeutic areas to drive growth, such as Taltz for psoriasis and migraine treatment Emgality, which won U.S. approval last year.

  • MarketWatch22 days ago

    Eli Lilly's stock jumps after profit and revenue beats, raised guidance

    Shares of Eli Lilly & Co. rallied 1.5% in premarket trading Tuesday, after the drug maker reported a second-quarter profit and revenue that beat expectations and raised its full-year outlook. Net income was $1.33 billion, or $1.44 a share, after a loss of $259.9 million, or 25 cents a share, in the same period a year ago. Excluding non-recurring items, adjusted EPS rose to $1.50 from $1.48, above the FactSet consensus of $1.45. Revenue rose 1% to $5.64 billion, beating the FactSet consensus of $5.58 billion. Trulicity sales climbed 32% to $1.03 billion, just below the FactSet consensus of $1.08 billion, while Humalog sales fell 12% to $677.6 million but beat expectations of $659.7 million. For 2019, the company raised its adjusted EPS guidance range to $5.67 to $5.77 from $5.60 to $5.70. The stock has lost 6.1% year to date through Monday, while the SPDR Health Care Select Sector ETF has gained 6.9% and the S&P 500 has rallied 20.5%.